Literature DB >> 15010026

Treatment of Functional Dyspepsia.

Silvia Delgado-Aros1, Filippo Cremonini, Nicholas J. Talley.   

Abstract

Functional dyspepsia is a common chronic condition. It can have a major impact on quality of life and remains a large burden on healthcare resources. Its underlying mechanisms are not fully understood and therapies are mainly empirical. In this review, we summarize the best evidence on available therapeutic interventions in functional dyspepsia. Helicobacter pylori eradication, for those infected, is likely a safe and cost-effective strategy but benefits only a minority. Antisecretory agents such as proton-pump inhibitors and histamine-2 receptor antagonists have shown some benefit and are recommended as the first-line option in the absence of H. pylori infection. There is a lack of strong evidence of benefit from prokinetic agents, and cisapride, the most studied agent, is largely unavailable. Antidepressants need to be adequately tested in functional dyspepsia, but both psychotherapy and hypnotherapy interventions have shown promising results. Herbal therapies need further study in these patients. 5-Hydroxytryptamine3 (5-HT(3)) and 5-HT(4) receptor antagonists, and cholecystokinin type A and neurokinin receptor antagonists remain promising emerging therapies.

Entities:  

Year:  2004        PMID: 15010026     DOI: 10.1007/s11938-004-0033-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  49 in total

Review 1.  AGA technical review: evaluation of dyspepsia. American Gastroenterological Association.

Authors:  N J Talley; M D Silverstein; L Agréus; O Nyrén; A Sonnenberg; G Holtmann
Journal:  Gastroenterology       Date:  1998-03       Impact factor: 22.682

2.  Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal.

Authors:  F Simonin; O Valverde; C Smadja; S Slowe; I Kitchen; A Dierich; M Le Meur; B P Roques; R Maldonado; B L Kieffer
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

3.  Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.

Authors:  F Cremonini; S Delgado-Aros; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2003-02       Impact factor: 3.598

Review 4.  An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews.

Authors:  Paul Moayyedi; Jon Deeks; Nicholas J Talley; Brendan Delaney; David Forman
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864

Review 5.  Eradication of Helicobacter pylori for non-ulcer dyspepsia.

Authors:  P Moayyedi; S Soo; J Deeks; B Delaney; A Harris; M Innes; R Oakes; S Wilson; A Roalfe; C Bennett; D Forman
Journal:  Cochrane Database Syst Rev       Date:  2003

6.  Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin.

Authors:  R Gotthard; G Bodemar; U Brodin; K A Jönsson
Journal:  Scand J Gastroenterol       Date:  1988-01       Impact factor: 2.423

7.  The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.

Authors:  Francis Creed; Lakshmi Fernandes; Elspeth Guthrie; Stephen Palmer; Joy Ratcliffe; Nicholas Read; Christine Rigby; David Thompson; Barbara Tomenson
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

8.  Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors.

Authors:  L Kay; T Jørgensen
Journal:  Scand J Gastroenterol       Date:  1994-01       Impact factor: 2.423

9.  Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.

Authors:  M Dapoigny; J L Abitbol; B Fraitag
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

10.  Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.

Authors:  Silvia Delgado-Aros; Heather J Chial; Michael Camilleri; Lawrence A Szarka; Frank T Weber; Jutta Jacob; Irene Ferber; Sanna McKinzie; Duane D Burton; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-04       Impact factor: 4.052

View more
  4 in total

1.  Many patients continue using proton pump inhibitors after negative results from tests for reflux disease.

Authors:  Andrew J Gawron; Jami Rothe; Angela J Fought; Anita Fareeduddin; Erin Toto; Lubomyr Boris; Peter J Kahrilas; John E Pandolfino
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-22       Impact factor: 11.382

Review 2.  Pathogenesis and therapy for idiopathic dyspepsia.

Authors:  Jan Tack; Sébastien Kindt
Journal:  Curr Gastroenterol Rep       Date:  2005-12

3.  Development and validation of a high throughput UPLC-MS/MS method for simultaneous quantification of esomeprazole, rabeprazole and levosulpiride in human plasma.

Authors:  Raja Haranadha Babu Chunduri; Gowri Sankar Dannana
Journal:  J Pharm Anal       Date:  2016-01-08

4.  Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia.

Authors:  R Lozano; Mg Peralta Concha; A Montealegre; L de Leon; J Ortiz Villalba; Ho Lee Esteban; M Cromeyer; Ja Rivas García; A Brossa; G Lluberes; E Izquierdo Sandí; H Burgos Quirós
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.